MedTrace Logo

506U78 in Treating Patients With Refractory Hematologic Cancer

NCT00002970 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2013-07-02

No results posted yet for this study

Summary

Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Conditions

  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood Lymphoblastic Lymphoma
  • T-cell Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG

nelarabine

Given IV

DRUG

methotrexate

Given IT

DRUG

cytarabine

Given IT

DRUG

therapeutic hydrocortisone

Given IT

Sponsors & Collaborators

  • Children's Cancer Group

    collaborator OTHER

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Stacey Berg · Children's Oncology Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-06-30
Primary Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002970 on ClinicalTrials.gov